{"id":"W4404194478","doi":"10.1177/17562848241293643","title":"Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Genentech; UCB Pharma; Sun Pharma; Astellas Pharma; Celltrion; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celltrion Healthcare; Gilead Sciences; GlaxoSmithKline; Tillotts Pharma; Amgen; Dr. Falk Pharma; Pfizer; Celgene","keywords":"Medicine; Ulcerative colitis; Adverse effect; Phases of clinical research; Phase (matter); Internal medicine; Clinical trial; Gastroenterology; Intensive care medicine; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01391959,0.0006391067,0.002199523,0.0006401825,0.0002812205,0.0009522276,0.0004101363,0.000668645,0.001229819],"category_scores_gemma":[0.009495134,0.0002992746,0.004643565,0.0009179342,0.0004223804,0.0006260268,0.0004388978,0.001144516,0.000114465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004227468,"about_ca_system_score_gemma":0.0006578505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000201733,"about_ca_topic_score_gemma":0.0006329495,"domain_scores_codex":[0.9916233,0.005413919,0.001024089,0.0006603515,0.001024316,0.0002540449],"domain_scores_gemma":[0.9820187,0.01028901,0.005365429,0.0007442972,0.0006571545,0.0009253614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6018686,0.002070113,0.2960828,0.003396716,0.03715604,0.0003574875,0.0001815471,0.002096267,0.005564109,0.0001732559,0.001856726,0.04919633],"study_design_scores_gemma":[0.1118047,0.1020656,0.753089,0.0002933946,0.02179267,0.000984498,0.0001859981,0.003527888,0.001544879,0.0003153909,0.004291771,0.0001041339],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845185,0.01150687,0.0006615592,0.0001657969,0.00006201195,0.0008251612,0.001373067,0.00002150307,0.0008655598],"genre_scores_gemma":[0.9950699,0.001866906,0.0004920562,0.0002260598,0.000108054,0.0004771879,0.00150161,0.00001024434,0.0002480419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01391959,"threshold_uncertainty_score":0.07361472,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01593308882847572,"score_gpt":0.3510217434978404,"score_spread":0.3350886546693647,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}